IBEX 35
11.032,30 -128,20 (-1,15%) Euro Stoxx 50
4.907,30 -40,43 (-0,82%) Dólar/Euro
1,0694 -0,0013 (-0,12%) Petróleo Brent
85,17 -0,54 (-0,63%) Oro
2.334,90 -34,10 (-1,44%) Bitcoin EUR
59.998,34 -728,85 (-1,20%)
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp.
1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
United States
702 514 4174
https://www.pasithea.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 8
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman | 250k | N/A | 1948 |
| Dr. Tiago Reis Marques M.D., Ph.D. | CEO & Director | 480k | N/A | 1977 |
| Mr. Daniel H. Schneiderman | Chief Financial Officer | 345,94k | N/A | 1978 |
| Dr. Graeme Currie Ph.D. | Chief Development Officer | 346,62k | N/A | 1967 |
| Dr. Yassine Bendiabdallah Ph.D. | COO & Head of UK Clinics | N/A | N/A | 1984 |
Descripción
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Gobierno corporativo
El ISS Governance QualityScore de Pasithea Therapeutics Corp., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
